Emma Walmsley, GlaxoSmithKline CEO (Kevin Dietsch/Pool via CNP/Alamy)

Glax­o­SmithK­line hus­tles the 7th PD-1 past the fin­ish line with Jem­per­li. But how big will up­take be?

Every­thing came up sev­ens for Glax­o­SmithK­line on Thurs­day as the phar­ma notched the sev­enth PD-1 ap­proval sev­en years af­ter the first such drugs were OK’ed in Keytru­da and Op­di­vo. But will it bring GSK good for­tune?

The FDA grant­ed ac­cel­er­at­ed ap­proval to dostar­limab, to be brand­ed Jem­per­li, to treat re­cur­rent or ad­vanced en­dome­tri­al can­cer in a spe­cif­ic sub­set of pa­tients fol­low­ing plat­inum-based chemo. It’s a drug that came to GSK through its buy­out of Tesaro, which it snapped up for $5.1 bil­lion back in De­cem­ber 2018.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.